The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort

Lupus
Fabrizio ContiGuido Valesini

Abstract

Literature data suggest a significantly higher mortality in patients affected by systemic lupus erythematosus (SLE) developing chronic damage. Therefore, damage prevention is a major goal in the management of SLE patients. In the present study, we assessed damage by means of the Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI), in a large cohort of SLE patients. Additionally, we aimed at evaluating its association with demographic and clinical features as well as with disease activity and laboratory findings. We enrolled consecutive patients affected by SLE diagnosed according to the American College of Rheumatology (ACR) 1997 revised criteria. Chronic damage was determined by SDI calculated at the last examination in all patients with at least six months of follow-up. Disease activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); flare was defined as an increase of SLEDAI-2K ≥ 4 compared with the previous visit. We evaluated 349 SLE patients (M/F 25/324, mean age ± SD 42.7 ± 12.4 years, mean disease duration ± SD 164.9 ± 105.2 months). Among the enrolled patients, 125 (35.8%) showed a SDI ≥ 1 (mean SDI ± SD 1.7 ± 0.9, ...Continue Reading

References

Aug 19, 2003·Rheumatology·G S AlarcónUNKNOWN LUMINA Study Group
Jul 21, 2006·Annals of the New York Academy of Sciences·Guido ValesiniFabrizio Conti
Aug 5, 2006·The American Journal of Medicine·Andrea DoriaSilvano Todesco
Feb 1, 2007·Arthritis and Rheumatism·Rosa M AndradeUNKNOWN LUMINA Study Group
Sep 17, 2008·The Journal of Rheumatology·Murray B UrowitzVernon T Farewell
Jul 25, 2009·Journal of Thrombosis and Haemostasis : JTH·V PengoUNKNOWN Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the Interna
Sep 3, 2010·Clinical Reviews in Allergy & Immunology·Guido Valesini, Fabrizio Conti
May 7, 2011·Autoimmunity Reviews·Cristiano AlessandriGuido Valesini
Jul 28, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Cristiano AlessandriMarina Pierdominici
Aug 31, 2012·Arthritis and Rheumatism·Michelle PetriLaurence S Magder
Jun 22, 2013·Seminars in Arthritis and Rheumatism·Emily J SuttonIan N Bruce
Jan 18, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Fabrizio ContiRachele Riganò
Jun 3, 2014·Lancet·Larissa LisnevskaiaDavid Isenberg

❮ Previous
Next ❯

Citations

Jun 24, 2016·PloS One·Ioannis ParodisIva Gunnarsson
May 24, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Jean-Christophe GrisJean-Pierre Balducchi
Sep 21, 2017·Clinical Rheumatology·Liying PengXiaofeng Zeng
Mar 31, 2019·Annals of the Rheumatic Diseases·Antonis FanouriakisDimitrios T Boumpas
May 17, 2019·Expert Review of Clinical Immunology·Chi Chiu Mok
Jun 7, 2019·Lupus Science & Medicine·Antonis Fanouriakis, George Bertsias
Dec 1, 2020·Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia·Rahana Abd RahmanAni Amelia Zainuddin
Mar 3, 2021·Seminars in Arthritis and Rheumatism·Fulvia CeccarelliFabrizio Conti

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

Statistical Package for Social Sciences ( SPSS

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.